Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pulmozyme--Dornase alfa

C Gutteridge, R J Kuhn

    Pediatric Nursing
    |May 1, 1994
    PubMed
    Summary
    This summary is machine-generated.

    Dornase alfa is a new drug for cystic fibrosis (CF) patients, improving lung function. While not a replacement for standard therapies, it offers an effective treatment option for a long-standing medical challenge.

    Related Experiment Videos

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The integration of transabdominal ultrasound simulators into an ultrasound curriculum.

    Ultrasound (Leeds, England)·2019
    Same author

    Tobramycin pharmacokinetics in patients with cystic fibrosis before and after bilateral lung transplantation.

    Transplant infectious disease : an official journal of the Transplantation Society·2011
    Same author

    Detection of membrane protein two-dimensional crystals in living cells.

    Biophysical journal·2010
    Same author

    Association of the pr peptides with dengue virus at acidic pH blocks membrane fusion.

    Journal of virology·2009
    Same author

    Protein kinase G phosphorylates mosquito-borne flavivirus NS5.

    Journal of virology·2009
    Same author

    Treating the asthmatic child with dry powder inhalers: a possible breakthrough.

    Pediatric nursing·2002
    Same journal

    Weight Management Clinic for the Treatment of a 14-Year-Old Female with Sudden Weight Gain.

    Pediatric nursing·2018
    Same journal

    Supporting Youth Aging Out of Foster Care.

    Pediatric nursing·2018
    Same journal

    Mentoring Practice and Mentoring Benefit 6: Equipping for Leadership and Leadership Readiness – An Overview and Application to Practice Using Mentoring Activities.

    Pediatric nursing·2018
    Same journal

    Children’s Exposure to Secondhand Smoke, Parental Nicotine Dependence, and Motivation to Quit Smoking.

    Pediatric nursing·2018
    Same journal

    Parental Knowledge about Urban Preschool Children’s Oral Health Risk.

    Pediatric nursing·2018
    Same journal

    Impacting Parental Vaccine Decision-Making.

    Pediatric nursing·2018
    See all related articles

    Area of Science:

    • Pulmonology
    • Pharmacology
    • Genetics

    Background:

    • Cystic Fibrosis (CF) is a genetic disorder affecting the lungs.
    • Pulmonary complications are a major cause of morbidity and mortality in CF.
    • Previous therapeutic options for CF lung disease have been limited.

    Purpose of the Study:

    • To introduce Dornase alfa as a novel therapeutic agent for cystic fibrosis.
    • To evaluate the efficacy of Dornase alfa in improving lung function in CF patients.

    Main Methods:

    • Clinical trials were conducted to assess the drug's effectiveness.
    • Lung function parameters were measured before and after treatment.

    Main Results:

    • Dornase alfa demonstrated significant improvements in lung function.
  • The drug provides a new treatment avenue for CF-related lung issues.

    • Conclusions:

    • Dornase alfa is an effective adjunctive therapy for cystic fibrosis.
    • The drug addresses a critical unmet need in CF patient care.